<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928654</url>
  </required_header>
  <id_info>
    <org_study_id>Lasercomparison</org_study_id>
    <nct_id>NCT01928654</nct_id>
  </id_info>
  <brief_title>Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema</brief_title>
  <official_title>Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luigi Sacco University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luigi Sacco University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macular edema is the most important cause of visual impairment in diabetic patients.
      Intravitreal injections of antiVEGF (vascular endothelial growth factor) agents and laser
      treatment are two effective therapies for stabilising visual acuity. However, antiVEGF
      therapy is very expensive and potentially needs to to be repeated for all patients life.
      Laser treatment, according to modified ETDRS (early treatment diabetic retinopathy study),
      produces retinal burns with possible negative consequences such as alterations in the visual
      fields.

      With micropulse treatment modality laser energy is delivered in short pulses (&quot;micropulses&quot;)
      rather than as a continuous wave. In this way the amount of energy delivered to the retina
      and retinal pigment epithelium (RPE) is significantly reduced. This finer control of the
      photothermal effects should avoid any retinal and RPE damage. At the same time, according to
      several published reports, the efficacy of treatment appears to be equivalent to conventional
      laser therapy.

      Previous studies investigated the effects of 810nm micropulse laser therapy. Recently, this
      treatment modality has been made available also with 577nm wavelength, which corresponds to
      the maximum absorption level for blood. Aim of this study is to assess the safety and
      efficacy of 577nm micropulse laser treatment compared to conventional modified ETDRS laser
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in visual acuity (ETDRS letters)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in central retinal thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Central retinal thickness corresponds to the mean retinal thickness within the 1-mm central subfield centred on the fovea. This measurement is obtained with Spectralis spectral-domain optical coherence tomography (SD-OCT) (Heidelberg Engineering, Germany).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients gaining ETDRS lines</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients that gain 1, 2, or 3 ETDRS lines of visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients losing ETDRS lines</measure>
    <time_frame>12 months</time_frame>
    <description>PErcentage of patients that loose 1, 2, or 3 ETDRS lines of visual acuity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Micropulse laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sub-threshold laser treatment covering the area of retinal thickening with a dense pattern</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser modified ETDRS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Macular treatment using the modified ETDRS protocol, with barely visible laser burns to close microaneurysms, or with a grid pattern in the area of retinal thickening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Micropulse laser treatment</intervention_name>
    <description>Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.</description>
    <arm_group_label>Micropulse laser treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser modified ETDRS</intervention_name>
    <description>Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.</description>
    <arm_group_label>Laser modified ETDRS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent prior to study entry

          -  male or female patients &gt;= 18 years of age

          -  patients with diagnosis of diabetes type 1 or 2 and clinically significant macular
             edema

          -  visual impairment due to clinically significant diabetic macular edema

          -  best-corrected visual acuity included between 21 and 74 ETDRS letters

          -  central retinal thickness greater than 320 micron (Spectralis SD-OCT, Heidelberg
             Engineering, Germany)

          -  leakage and/or micro aneurysm in fluorescein angiography images within the area of
             retinal thickening

          -  HbA1C â‰¤10% with well-controlled blood pressure and renal function

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Giani, MD</last_name>
    <phone>+39023904</phone>
    <phone_ext>2901</phone_ext>
    <email>andrea.giani@unimi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Caimi, MD</last_name>
    <phone>+39023904</phone>
    <phone_ext>2441</phone_ext>
    <email>antonio.caimi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye Clinic - Luigi Sacco University Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Giani, MD</last_name>
      <phone>+39023904</phone>
      <phone_ext>2901</phone_ext>
      <email>andrea.giani@unimi.it</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Caimi, MD</last_name>
      <phone>+39023904</phone>
      <phone_ext>2441</phone_ext>
      <email>antonio.caimi@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Giani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Staurenghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigi Bonavia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Caimi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Luigi Sacco University Hospital</investigator_affiliation>
    <investigator_full_name>Giovanni Staurenghi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Edema</keyword>
  <keyword>Diabetic</keyword>
  <keyword>Laser</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

